Research presented at the Society for Maternal-Fetal Medicine (SMFM) 2026 Pregnancy Meeting has delivered significant reassurance to expectant parents and public health officials worldwide, confirming that receiving an mRNA COVID-19 vaccine shortly before or at any point during pregnancy is not associated with an increased risk of autism or other developmental disorders in children. These findings, stemming from a rigorous prospective study, provide crucial long-term data on the health outcomes of children whose mothers were vaccinated around the time of conception or during gestation, addressing a key concern that has contributed to vaccine hesitancy among pregnant individuals. The comprehensive investigation, conducted by researchers within the esteemed Maternal-Fetal Medicine Units Network, systematically evaluated 434 children between 18 months and 30 months of age. This critical developmental window allowed for thorough screening for early signs of autism spectrum disorder (ASD) and other potential developmental delays. The study’s robust methodology and the prominence of its presentation at a leading maternal-fetal medicine conference underscore the weight and importance of its conclusions. The Landscape of COVID-19 Vaccination in Pregnancy The emergence of the SARS-CoV-2 virus in late 2019 rapidly transformed global public health, leading to an unprecedented scientific effort to develop vaccines. The messenger ribonucleic acid (mRNA) vaccines, representing a novel platform, were among the first to receive emergency use authorization. While their efficacy in preventing severe COVID-19 was quickly established, concerns naturally arose regarding their safety, particularly for vulnerable populations like pregnant individuals and their unborn children. Historically, the introduction of new medications or vaccines has often been met with caution in pregnancy due to ethical considerations in clinical trials. Pregnant individuals were initially excluded from the pivotal phase 3 COVID-19 vaccine trials, leading to a period where recommendations were based on extrapolations from non-pregnant populations and preclinical data. However, as real-world data accumulated, a clear picture emerged: pregnant individuals faced a higher risk of severe COVID-19 outcomes, including hospitalization, intensive care unit admission, and even death, compared to their non-pregnant counterparts. Furthermore, COVID-19 during pregnancy was linked to increased risks of preterm birth, preeclampsia, and stillbirth. Recognizing these heightened risks, major public health organizations globally, including the U.S. Centers for Disease Control and Prevention (CDC), the American College of Obstetricians and Gynecologists (ACOG), and the World Health Organization (WHO), progressively strengthened their recommendations for COVID-19 vaccination during all stages of pregnancy. In the United States, both mRNA vaccines (Pfizer-BioNTech and Moderna) and protein subunit vaccines (Novavax) are recommended, all considered safe and effective in safeguarding both maternal and infant health. This latest research directly reinforces these existing recommendations with critical long-term developmental outcome data. Unpacking the Study’s Rigor and Methodology The investigation, formally titled "Association between SARS-CoV-2 vaccine in pregnancy and child neurodevelopment at 18-30 months," was designed as a prospective, multi-center, and observational study. This design is highly valued in clinical research as it follows participants forward in time, collecting data as events unfold, thus minimizing recall bias inherent in retrospective studies. Data collection for the child developmental assessments took place between May 2024 and March 2025, allowing for a focused and consistent evaluation period. The study population comprised 434 toddlers, carefully divided into two equally sized groups. Half of the children (217) were born to mothers who had received at least one dose of an mRNA COVID-19 vaccine either during pregnancy or within 30 days prior to becoming pregnant. The remaining 217 children served as the control group, born to mothers who did not receive an mRNA vaccine during or within 30 days prior to pregnancy. This clear distinction allowed for a direct comparison of developmental trajectories between vaccinated and unvaccinated maternal groups. To ensure the most accurate comparison possible, researchers employed a meticulous matching process. Vaccinated mothers were paired with unvaccinated mothers based on several critical demographic and clinical factors, including the location of delivery (hospital, birth center, etc.), the exact date of delivery, insurance status, and racial background. This rigorous matching strategy aimed to minimize potential confounding variables that could otherwise influence child development outcomes, thereby isolating the effect of maternal vaccination. Furthermore, certain pregnancies were explicitly excluded from both groups to maintain homogeneity and focus the study on otherwise healthy, full-term births. These exclusions included pregnancies that ended before 37 weeks of gestation (preterm births), those involving multiple babies (twins, triplets, etc.), or those that resulted in a child with a major congenital malformation. By controlling for these factors, the study strengthened its ability to attribute any observed differences or, in this case, lack thereof, directly to the vaccination status. Comprehensive Assessment of Child Development When the children reached the age range of 18 to 30 months (1 ½ to 2 ½ years), a period crucial for rapid neurodevelopment, researchers utilized a battery of well-validated screening tools. The primary assessment instrument was the Ages and Stages Questionnaire Version 3 (ASQ-3). The ASQ-3 is a widely recognized, parent-completed developmental screening tool that measures progress across five key developmental domains: Communication: Assessing language comprehension and expression. Gross Motor Skills: Evaluating large muscle movements, such as walking, running, and jumping. Fine Motor Skills: Assessing small muscle coordination, like grasping and manipulating objects. Problem Solving: Measuring cognitive abilities related to understanding and resolving challenges. Personal Social Interaction: Evaluating social engagement, self-help skills, and emotional responses. In addition to the ASQ-3, the research team also reviewed results from other established tools to further corroborate and deepen their understanding of behavioral and developmental patterns. These included the Child Behavior Checklist (CBCL), which assesses a wide range of behavioral and emotional problems; the Modified Checklist for Autism in Toddlers, Revised with Follow-up (M-CHAT-R/F), a highly sensitive screening tool specifically for autism spectrum disorder; and the Early Childhood Behavior Questionnaire (ECBQ), which measures temperament dimensions in young children. The use of multiple, complementary assessment tools significantly enhanced the reliability and validity of the study’s findings. Reassuring Conclusions from Leading Experts The results of this exhaustive investigation were unequivocally positive. George R. Saade, MD, a senior researcher on the study and a distinguished Professor and Chair of Obstetrics and Gynecology, as well as Associate Dean for Women’s Health, at Macon & Joan Brock Virginia Health Sciences at Old Dominion University in Norfolk, VA, articulated the central finding: "Neurodevelopment outcomes in children born to mothers who received the COVID-19 vaccine during or shortly before pregnancy did not differ from those born to mothers who did not receive the vaccine." This statement directly addresses the concerns about vaccine-induced developmental issues, providing clear evidence of no adverse effect. Brenna L. Hughes, MD, MSc, the Edwin Crowell Hamblen Distinguished Professor of Reproductive Biology and Family Planning and Interim Chair of the Department of Obstetrics and Gynecology at Duke University in Raleigh, NC, further emphasized the significance of the study. Dr. Hughes noted, "This study, conducted through a rigorous scientific process in an NIH clinical trials network, demonstrates reassuring findings regarding the long-term health of children whose mothers received COVID-19 vaccination during pregnancy." Her comment highlights the study’s credibility, stemming from its execution within a National Institutes of Health (NIH) clinical trials network, which adheres to the highest standards of scientific rigor and ethical oversight. Funding, Disclosure, and Publication The research received vital funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a component of the NIH. This federal funding underscores the public health importance and scientific merit attributed to the investigation. The authors maintained full transparency, noting that the conclusions presented were their own and did not necessarily reflect the official views of the National Institutes of Health, a standard practice to ensure independent scientific interpretation. The full details of the study, presented as oral abstract #8, titled "Association between SARS-CoV-2 vaccine in pregnancy and child neurodevelopment at 18-30 months," are slated for publication in the February 2026 issue of PREGNANCY, the official peer-reviewed medical journal of the Society for Maternal-Fetal Medicine. This publication in a leading specialist journal ensures that the findings will undergo further scrutiny by the scientific community and become a permanent part of the medical literature, accessible to clinicians and researchers worldwide. Broader Implications for Public Health and Trust These findings represent a critical milestone in the ongoing effort to understand the long-term safety profile of COVID-19 vaccines, particularly in the context of pregnancy. For public health authorities like the CDC and WHO, this research provides robust, evidence-based data to strengthen existing recommendations and combat vaccine misinformation. It offers a powerful counter-narrative to unsubstantiated claims linking vaccines to autism, a persistent false claim that has plagued vaccine confidence for decades. For expectant parents, this study offers profound peace of mind. The decision to vaccinate during pregnancy is deeply personal and often fraught with anxiety, especially given the natural desire to protect one’s unborn child. This research directly addresses one of the most significant anxieties, providing scientific assurance that choosing to vaccinate against COVID-19 does not jeopardize a child’s neurodevelopmental trajectory. This can lead to increased vaccine uptake among pregnant individuals, ultimately enhancing protection for both mothers and infants against the severe consequences of COVID-19. The study also reinforces the broader scientific consensus that vaccines, particularly those recommended during pregnancy (such as influenza and Tdap), are safe and beneficial. It adds to a growing body of literature that has consistently demonstrated the safety of COVID-19 vaccines in pregnancy across various outcomes, including miscarriage, preterm birth, stillbirth, and adverse neonatal outcomes. While this study provides compelling evidence, continued vigilance and research remain paramount. Future studies may explore even longer-term neurodevelopmental outcomes beyond 30 months, investigate specific subpopulations, or delve deeper into the mechanisms of maternal antibody transfer and its protective effects on the developing fetus. However, for now, the message is clear and reassuring: mRNA COVID-19 vaccination in pregnancy is not linked to autism or other developmental disorders, offering a significant win for public health and the well-being of families globally. Post navigation Shingles Vaccine Offers Significant Cardiovascular Protection for High-Risk Individuals, Research Shows
